HIT KIT, Inc.

HITKIT

Pharmaceuticals, namely, a partial agonist of N-methyl-D-aspartame (NMDA) receptors at low dose and a partial antagonist of NMDA at high dose, an inhibitor of microglial activation, and a modulator of NMDA receptors; antibiotics; pharmaceuticals and antibiotics for the treatment or prevention of neurological symptoms or conditions associated with concussion or traumatic brain injury; pharmaceuticals and antibiotics for reversing the damage caused by concussion or traumatic brain injury;HIT KIT;Retail store services featuring drug delivery systems, pill packets, pharmaceuticals, antibiotics, and drugs for the treatment or prevention of neurological symptoms or conditions associated with concussion or traumatic brain injury;Medical services, namely, providing medical services using drug delivery systems, pill packets, pharmaceuticals, antibiotics, and drugs for the treatment or prevention of neurological symptoms or conditions associated with concussion or traumatic brain injury;Drug delivery system, namely, an intramuscular autoinjector and an intramuscular drug delivery autoinjector; drug delivery system for administering drugs for the treatment or prevention of neurological symptoms or conditions associated with concussion or traumatic brain injury, namely, an intramuscular autoinjector, and an intramuscular needle-based injection system; an intramuscular needle-based injection system for administering drugs for the treatment or prevention of neurological symptoms or conditions associated with concussion or traumatic brain injury; drug delivery system for reversing the damage caused by concussion or traumatic brain injury, namely, intramuscular autoinjector and an intramuscular needle-based injection system;